|
1
|
Spizzo R, Almeida MI, Colombatti A and
Calin GA: Long non-coding RNAs and cancer: A new frontier of
translational research? Oncogene. 31:4577–4587. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Nobili L, Ronchetti D, Agnelli L, Taiana
E, Vinci C and Neri A: Long non-coding RNAs in multiple myeloma.
Genes (Basel). 9(pii): E692018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wang H, Wang J, Liang CF and Zhou T:
Expression of long non-coding RNA PRAL as a potential biomarker for
diagnosis in non-small-cell lung cancer patients is associated with
the inhibition of cell proliferation and metastasis. Clin Lab.
64:1341–1348. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhang ZS, Wang J, Zhu BQ and Ge L: Long
noncoding RNA UCA1 promotes multiple myeloma cell growth by
targeting TGF-β. Eur Rev Med Pharmacol Sci. 22:1374–1379.
2018.PubMed/NCBI
|
|
5
|
Chen L, Hu N, Wang C, Zhao H and Gu Y:
Long non-coding RNA CCAT1 promotes multiple myeloma progression by
acting as a molecular sponge of miR-181a-5p to modulate HOXA1
expression. Cell Cycle. 17:319–329. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Spitzer TR, Sachs DH and Cosimi B:
Multiple myeloma. N Engl J Med. 364:23642011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kuehl WM and Bergsagel PL: Molecular
pathogenesis of multiple myeloma and its premalignant precursor. J
Clin Invest. 122:3456–3463. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Anderson KC: Progress and paradigms in
multiple myeloma. Clin Cancer Res. 22:5419–5427. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Robak P, Drozdz I, Szemraj J and Robak T:
Drug resistance in multiple myeloma. Cancer Treat Rev. 70:199–208.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Rinn JL, Kertesz M, Wang JK, Squazzo SL,
Xu X, Brugmann SA, Goodnough LH, Helms JA, Farnham PJ, Segal E and
Chang HY: Functional demarcation of active and silent chromatin
domains in human HOX loci by noncoding RNAs. Cell. 129:1311–1323.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gupta RA, Shah N, Wang KC, Kim J, Horlings
HM, Wong DJ, Tsai MC, Hung T, Argani P, Rinn JL, et al: Long
non-coding RNA HOTAIR reprograms chromatin state to promote cancer
metastasis. Nature. 464:1071–1076. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tang Q and Hann SS: HOTAIR: An oncogenic
long non-coding RNA in human cancer. Cell Physiol Biochem.
47:893–913. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Xing CY, Hu XQ, Xie FY, Yu ZJ, Li HY,
Bin-Zhou, Wu JB, Tang LY and Gao SM: Long non-coding RNA HOTAIR
modulates c-KIT expression through sponging miR-193a in acute
myeloid leukemia. FEBS Lett. 589:1981–1987. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wu Y and Wang H: LncRNA NEAT1 promotes
dexamethasone resistance in multiple myeloma by targeting
miR-193a/MCL1 pathway. J Biochem Mol Toxicol. 32:Jan;2018.doi:
10.1002/jbt.22008. View Article : Google Scholar :
|
|
17
|
Li QY, Chen L, Hu N and Zhao H: Long
non-coding RNA FEZF1-AS1 promotes cell growth in multiple myeloma
via miR-610/Akt3 axis. Biomed Pharmacother. 103:1727–1732. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kumar SK, Rajkumar V, Kyle RA, van Duin M,
Sonneveld P, Mateos MV, Gay F and Anderson KC: Multiple myeloma.
Nat Rev Dis Primers. 3:170462017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Moreaux J, Hose D, Reme T, Jourdan E,
Hundemer M, Legouffe E, Moine P, Bourin P, Moos M, Corre J, et al:
CD200 is a new prognostic factor in multiple myeloma. Blood.
108:4194–4197. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Perosa F, Minoia C, Favoino E, Prete M and
Dammacco F: Staging multiple myeloma patients with active disease
using serum levels of beta2m-free HLA class I heavy chain together
with IgM or platelet count. Blood Cells Mol Dis. 42:71–76. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bhan A, Soleimani M and Mandal SS: Long
noncoding RNA and cancer: A new paradigm. Cancer Res. 77:3965–3981.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bolha L, Ravnik-Glavač M and Glavač D:
Long noncoding RNAs as biomarkers in cancer. Dis Markers.
2017:72439682017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Shen X, Zhang Y, Wu X, Guo Y, Shi W, Qi J,
Cong H, Wang X, Wu X and Ju S: Upregulated lncRNA-PCAT1 is closely
related to clinical diagnosis of multiple myeloma as a predictive
biomarker in serum. Cancer Biomark. 18:257–263. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li N, Wang Y, Liu X, Luo P, Jing W, Zhu M
and Tu J: Identification of circulating long noncoding RNA HOTAIR
as a novel biomarker for diagnosis and monitoring of non-small cell
lung cancer. Technol Cancer Res Treat. Jan 1–2017.doi:
10.1177/1533034617723754 (Epub ahead of print). View Article : Google Scholar
|
|
25
|
Elsayed ET, Salem PE, Darwish AM and Fayed
HM: Plasma long non-coding RNA HOTAIR as a potential biomarker for
gastric cancer. Int J Biol Markers. Apr 1–2018.doi:
10.1177/1724600818760244 (Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tan SK, Pastori C, Penas C, Komotar RJ,
Ivan ME, Wahlestedt C and Ayad NG: Serum long noncoding RNA HOTAIR
as a novel diagnostic and prognostic biomarker in glioblastoma
multiforme. Mol Cancer. 17:742018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang W, He X, Zheng Z, Ma X, Hu X, Wu D
and Wang M: Serum HOTAIR as a novel diagnostic biomarker for
esophageal squamous cell carcinoma. Mol Cancer. 16:752017.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Das M: Lenalidomide plus dexamethasone in
multiple myeloma. Lancet Oncol. 19:e122018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhao JJ, Chu ZB, Hu Y, Lin J, Wang Z,
Jiang M, Chen M, Wang X, Kang Y, Zhou Y, et al: Targeting the
miR-221-222/PUMA/BAK/BAX pathway abrogates dexamethasone resistance
in multiple myeloma. Cancer Res. 75:4384–4397. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Arora L, Kumar AP, Arfuso F, Chng WJ and
Sethi G: The role of signal transducer and activator of
transcription 3 (STAT3) and its targeted inhibition in
hematological malignancies. Cancers (Basel). 10(pii): E3272018.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Liu T, Fei Z, Gangavarapu KJ, Agbenowu S,
Bhushan A, Lai JC, Daniels CK and Cao S: Interleukin-6 and
JAK2/STAT3 signaling mediate the reversion of dexamethasone
resistance after dexamethasone withdrawal in 7TD1 multiple myeloma
cells. Leuk Res. 37:1322–1328. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhu S, Wang Z, Li Z, Peng H, Luo Y, Deng
M, Li R, Dai C, Xu Y, Liu S and Zhang G: Icaritin suppresses
multiple myeloma, by inhibiting IL-6/JAK2/STAT3. Oncotarget.
6:10460–10472. 2015. View Article : Google Scholar : PubMed/NCBI
|
